Results for 'diagnosis'
Redefining Ovarian Cancer Care with Biomarkers
Labcorp, Rebecca Previs, Kyle Strickland, ovarian cancer, diagnosis, biomarker, HRD, RB1, tumor biology
Exploring ovarian cancer, biomarkers HRD & RB1, and how Labcorp innovations are advancing precision oncology.
Sep 7th • 14 mins listen
Finding Success as a Rare Diseases MSL
rare diseases MSL, medical science liaison challenges, key opinion leaders engagement, patient diagnosis liaisons, rare disease territory coverage
In this episode, Giovanni Passiatore delves into the complexities of working in the rare diseases arena as an MSL. Giovanni shares his extensive background and provides insights into the unique challenges faced in this field, including strategies for effective territory coverage and engaging wi…
Jul 5th • 37 mins listen
Why Comprehensive Testing Matters - Ken Schlosser’s Lung Cancer Story
Labcorp, Rebecca Previs, Ken Schlosser, biomarker, lung cancer, ALK+, advocacy, precision
Biomarker testing helped Ken Schlosser live with stage IV lung cancer for over 6 years. Here's how it shaped his care plan from the start.
Jul 31st • 23 mins listen
Empowering Breast Cancer Patients: Biomarker Breakthroughs & Self-Advocacy
Rebecca Previs, Suzanne Garner, breast cancer, digital, biomarker, genetic testing, advocacy
Suzanne Garner’s journey shows how education, advocacy, and technology are reshaping breast cancer patient care and clinical trial access.
Oct 19th • 26 mins listen
Season 1, Episode 23: Revolutionizing Cancer Treatment with Paul Romness
Welcome back to the Pharmaverse, where we speak to the greatest voices in Pharma, to learn from their leadership and incredible careers! In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Paul Romness, CEO of OS Therapies. The conversation delves into the inspiring sto…
Nov 18th • 25 mins listen
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
Highlights From Today’s Episode “With next-generation sequencing (NGS), multiple biomarkers can be evaluated using one test. So, in cancer care, we’re learning that any given tumor may harbor a variety of variants. So, if we’re considering using in situ hybridization (ISH)…
Mar 30th • 47 mins listen